Dual CAR-T cell therapy for hard-to-treat B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This early-stage trial tests a new type of immune cell therapy (CAR-T cells) designed to target two markers found on B-cell lymphomas that haven't responded to standard treatments. The therapy uses nanobodies—smaller immune proteins—to help your own cells recognize and kill cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with B-cell lymphoma that has come back or stopped responding to at least 2 prior treatments (or 3 for slower-growing types)
- Age 18–75 years old
- Good overall health status (ECOG score 0–2, meaning you can do light activity)
- Adequate heart, lung, kidney, and liver function (specific blood and imaging tests required)
- Willing to use contraception for at least 1 year after receiving the CAR-T cells
- Expected to live more than 3 months from the start of the trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy that targets two markers (CD19 and CD20) on lymphoma cells. It is for patients whose lymphoma has come back or has not responded to standard treatments.
This trial tests a new type of CAR-T cell therapy that targets two markers (CD19 and CD22) on leukemia cells. It's for people whose B-cell acute lymphoblastic leukemia has come back or hasn't responded to other treatments.
This early-phase trial tests a special kind of immune cell treatment (CAR T cells) that targets CD20 and CD22 in people with relapsed or refractory B-cell cancers. It may help by attacking cancer cells that survived prior treatments, but it is still being studied for safety and early effectiveness.
This early-stage study tests a new type of immune cell therapy (CAR-T) that targets two proteins, CD19 and CD20, on your lymphoma cells. It is for people with aggressive B-cell lymphoma that has returned or not responded after several treatments. The goal is to see if this therapy can help shrink the cancer.
This trial tests a new type of CAR-T cell therapy designed to be stronger against B-cell lymphoma that has come back or not responded to previous treatments. The treatment uses your own immune cells, which are modified in a lab to better attack cancer cells.
This trial tests a CAR-T cell treatment made to target CD19 on lymphoma cells (PL001). It’s for people whose B-cell lymphoma has come back or not responded to standard treatments, aiming to shrink the cancer and help control the disease.
Hear when a new Relapsed/Refractory B-cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.